WARREN C FISKUS to Pyrimidines
This is a "connection" page, showing publications WARREN C FISKUS has written about Pyrimidines.
Connection Strength
0.542
-
Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res. 2011 Dec 01; 17(23):7347-58.
Score: 0.160
-
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006 Oct 01; 12(19):5869-78.
Score: 0.113
-
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood. 2006 Jul 15; 108(2):645-52.
Score: 0.109
-
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015 Sep 24; 126(13):1565-74.
Score: 0.052
-
Role of additional novel therapies in myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2012 Oct; 26(5):959-80.
Score: 0.043
-
Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res. 2009 May; 33(5):735-41.
Score: 0.033
-
Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 06; 33(6):1373-1386.
Score: 0.017
-
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009 Dec 03; 114(24):5024-33.
Score: 0.009
-
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 2005 Feb 15; 105(4):1768-76.
Score: 0.006